Taken together, these data confirm PARP-inhibitor-induced multinucleation in BRCA1- or BRCA2-deficient tumour cells, and suggest that failed mitosis may contribute to the cytotoxicity of PARP inhibition in these cancer cells. This evidence concerns the gene PARP1 and cancer.